Search

Your search keyword '"Badawy, Sherif M."' showing total 26 results
Start Over Author "Badawy, Sherif M." Publication Year Range This year
26 results on '"Badawy, Sherif M."'

3. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study

Author

Kahn, Justine, Brazauskas, Ruta, Bo-Subait, Stephanie, Buchbinder, David, Hamilton, Betty K, Schoemans, Hélène, Abraham, Allistair A, Agrawal, Vaibhav, Auletta, Jeffery J, Badawy, Sherif M, Beitinjaneh, Amer, Bhatt, Neel S, Broglie, Larisa, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, Cesar O, Gale, Robert Peter, Ganguly, Siddhartha, Hayashi, Robert J, Hematti, Peiman, Hildebrandt, Gerhard C, Inamoto, Yoshihiro, Kamble, Rammurti T, Koo, Jane, Lazarus, Hillard M, Mayo, Samantha J, Mehta, Parinda A, Myers, Kasiani C, Nishihori, Taiga, Prestidge, Tim, Rotz, Seth J, Savani, Bipin N, Schears, Raquel M, Sharma, Akshay, Stenger, Elizabeth, Ustun, Celalettin, Williams, Kirsten M, Vrooman, Lynda M, Satwani, Prakash, and Phelan, Rachel

Published
2024
Full Text
View/download PDF

5. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

7. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities

Author

Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad Bilal, Diaz Perez, Miguel Angel, Al-Homsi, A. Samer, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel M., Lazarus, Hillard M., Ciurea, Stefan, Badawy, Sherif M., Savani, Bipin N., Wirk, Baldeep, LeMaistre, C. Fred, Bhatt, Neel S., Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer M., Kelkar, Amar H., Yared, Jean A., Kindwall-Keller, Tamila, Winestone, Lena E., Steinberg, Amir, Arnold, Staci D., Seo, Sachiko, Preussler, Jaime M., Hossain, Nasheed M., Fingrut, Warren B., Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie E., Wood, William A., Rangarajan, Hemalatha G., Saber, Wael, and Hahn, Theresa

Published
2024
Full Text
View/download PDF

8. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients

Author

Zinter, Matt S., Brazauskas, Ruta, Strom, Joelle, Chen, Stella, Bo-Subait, Stephanie, Sharma, Akshay, Beitinjaneh, Amer, Dimitrova, Dimana, Guilcher, Greg, Preussler, Jaime, Myers, Kasiani, Bhatt, Neel S., Ringden, Olle, Hematti, Peiman, Hayashi, Robert J., Patel, Sagar, De Oliveira, Satiro Nakamura, Rotz, Seth, Badawy, Sherif M., Nishihori, Taiga, Buchbinder, David, Hamilton, Betty, Savani, Bipin, Schoemans, Hélène, Sorror, Mohamed, Winestone, Lena, Duncan, Christine, Phelan, Rachel, and Dvorak, Christopher C.

Published
2024
Full Text
View/download PDF

10. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Author

Ballen, Karen, Wang, Tao, He, Naya, Knight, Jennifer M., Hong, Sanghee, Frangoul, Haydar, Verdonck, Leo F., Steinberg, Amir, Diaz, Miguel A., LeMaistre, C. Fred, Badawy, Sherif M., Pu, Jeffrey J., Hashem, Hasan, Savani, Bipin, Sharma, Akshay, Lazarus, Hillard M., Abid, Muhammad Bilal, Tay, Jason, Rangarajan, Hemalatha G., Kindwall-Keller, Tamila, Freytes, Cesar O., Beitinjaneh, Amer, Winestone, Lena E., Gergis, Usama, Farhadfar, Nosha, Bhatt, Neel S., Schears, Raquel M., Gómez-Almaguer, David, Aljurf, Mahmoud, Agrawal, Vaibhav, Kuwatsuka, Yachiyo, Seo, Sachiko, Marks, David I., Lehmann, Leslie, Wood, William A., Hashmi, Shahrukh, and Saber, Wael

Published
2024
Full Text
View/download PDF

11. Mediators and Moderators of Cognitive-Behavioral Digital Health Intervention for Youth with Sickle Cell Disease Pain

Author

Srinakarin, Kavin, primary, Sanpoori, Shwetha, additional, Lalloo, Chitra, additional, Zhou, Chuan, additional, Dampier, Carlton, additional, Zempsky, William, additional, Badawy, Sherif M., additional, Bakshi, Nitya, additional, Ko, Yeon Joo, additional, Nishat, Fareha, additional, Stinson, Jennifer N., additional, and Palermo, Tonya M., additional

Published
2024
Full Text
View/download PDF

12. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Author

Bos, Saskia, primary, Murray, John, additional, Marchetti, Monia, additional, Cheng, Guang-Shing, additional, Bergeron, Anne, additional, Wolff, Daniel, additional, Sander, Clare, additional, Sharma, Akshay, additional, Badawy, Sherif M., additional, Peric, Zinaida, additional, Piekarska, Agnieszka, additional, Pidala, Joseph, additional, Raj, Kavita, additional, Penack, Olaf, additional, Kulkarni, Samar, additional, Beestrum, Molly, additional, Linke, Andrea, additional, Rutter, Matthew, additional, Coleman, Courtney, additional, Tonia, Thomy, additional, Schoemans, Hélène, additional, Stolz, Daiana, additional, and Vos, Robin, additional

Published
2024
Full Text
View/download PDF

14. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy

Author

Lee, Catherine J., Wang, Tao, Chen, Karen, Arora, Mukta, Brazauskas, Ruta, Spellman, Stephen R., Kitko, Carrie, MacMillan, Margaret L., Pidala, Joseph A., Badawy, Sherif M., Bhatt, Neel, Bhatt, Vijaya R., DeFilipp, Zachariah, Diaz, Miguel A., Farhadfar, Nosha, Gadalla, Shahinaz, Hashmi, Shahrukh, Hematti, Peiman, Hossain, Nasheed M., Inamoto, Yoshihiro, Lekakis, Lazaros J., Sharma, Akshay, Solomon, Scott, Lee, Stephanie J., and Couriel, Daniel R.

Published
2024
Full Text
View/download PDF

15. What is in a name: defining pediatric refractory ITP

Author

Nakano, Taizo A., Grimes, Amanda B., Klaassen, Robert J., Lambert, Michele P., Neunert, Cindy, Rothman, Jennifer A., Shimano, Kristin A., Amend, Christina, Askew, Megan, Badawy, Sherif M., Baker, Jillian M., Breakey, Vicky, Crary, Shelley, Davini, Monica, Fritch Lilla, Stephanie, Gilbert, Megan, Hays, Taru, Hege, Kerry, Hillier, Kirsty, Jacobson-Kelly, Amanda, Kaicker, Shipra, Kim, Taylor O., Kochhar, Manpreet, Leblanc, Thierry, Martinelli, Marie, Nunez, Mara, Remiker, Allison, Schultz, Corrina, Sharma, Ruchika, and Grace, Rachael F.

Abstract

There are no agreed upon terminology to define “refractory” pediatric immune thrombocytopenia (ITP). Guidelines are therefore limited to arbitrary and outdated definitions. The Pediatric ITP Consortium of North America held a meeting in 2023 to define this entity. With 100% agreement, the faculty established that pediatric ITP that is refractory to emergent therapy could be defined as no platelet response after treatment with all eligible emergent pharmacotherapies. With 100% agreement, the working group established that pediatric patients with ITP that continue to demonstrate high disease burden and/or no platelet response despite treatment with multiple classes of disease-modifying therapies represent a challenging subset of ITP. These patients are at higher risk of ongoing disease burden and merit additional investigation as well as consideration for clinical trials or novel therapies. Future efforts to define disease burden and disease response will be completed in collaboration with the ITP International Working Group.

Published
2024
Full Text
View/download PDF

17. Mental health, pain and likelihood of opioid misuse among adults with sickle cell disease

Author

Jonassaint, Charles R., primary, Parchuri, Ektha, additional, O'Brien, Julia A., additional, Lalama, Christina M., additional, Lin, Jonathan, additional, Badawy, Sherif M., additional, Hamm, Megan E., additional, Stinson, Jennifer, additional, Lalloo, Chitra, additional, Carroll, C. Patrick, additional, Saraf, Santosh L., additional, Gordeuk, Victor R., additional, Cronin, Robert, additional, Shah, Nirmish, additional, Lanzkron, Sophie M., additional, Liles, Darla, additional, Trimnell, Cassandra, additional, Bailey, Lakiea, additional, Lawrence, Raymona H., additional, and Abebe, Kaleab Z., additional

Published
2024
Full Text
View/download PDF

21. Health‐related quality of life with standard and curative therapies in thalassemia: A narrative literature review.

Author

Shah, Richa and Badawy, Sherif M.

Subjects
*QUALITY of life, *LITERATURE reviews, *NARRATIVE therapy, *BLOOD transfusion, *PHYSICAL mobility, *FETAL hemoglobin
Abstract

Health‐related quality of life (HRQOL) is a patient‐reported outcome that assesses the impact of a disease or illness on different domains of a patient's life. Different general and disease‐specific measures can be used to evaluate HRQOL. This article aimed to summarize the evidence for HRQOL among patients with transfusion‐dependent (TDT) and non‐transfusion‐dependent thalassemia (NTDT). We included HRQOL data related to standard therapy with blood transfusions, iron chelation, and/or luspatercept in TDT and NTDT, as well as curative therapies for TDT, including hematopoietic stem cell transplant (HSCT) and gene therapy. Patients with thalassemia had worse HRQOL scores compared to the general population, and chronic pain was seen to increase in frequency and severity over time with age. NTDT patients reported worse physical health and functioning, mental health, general health, and vitality than TDT patients. However, TDT patients reported worse pain, change in health, and social support than NTDT. Most therapies improved overall HRQOL among thalassemia patients. Deferasirox, an oral iron chelator, was associated with more HRQOL benefits compared to deferoxamine, an intravenous iron chelator. Luspatercept showed clinically meaningful improvement in physical functioning among TDT and NTDT. Furthermore, HSCT and gene therapy were associated with better physical, emotional, and mental domains scores. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. International Roughness Index Prediction for Jointed Plain Concrete Pavements Using Regression and Machine Learning Techniques

Author

Suliman, Amany M., Awed, Ahmed M., Abd El-Hakim, Ragaa T., and El-Badawy, Sherif M.

Abstract

Rigid pavements are recently gaining vast interest for their durability and large traffic volume endurance. This raises the need for a robust method to predict their long-term performance to support decisions on their future maintenance and rehabilitation requirements. One of the most descriptive parameters of pavement ride quality is the International Roughness Index (IRI). IRI can be used as a performance indicator for the level of serviceability of rigid pavement. This study presents the evaluation of 21 variables covering climate, traffic, and structural parameters in predicting IRI for jointed plain concrete pavement (JPCP) sections using 1,414 data points acquired from the Long-Term Pavement Performance (LTPP) database. It was found that only 10 variables are significant in the IRI prediction for JPCP. Moreover, four modeling techniques were applied, namely, linear regression, multivariate adaptive regression splines, Gaussian process regression, and artificial neural network. It was found that a deep ANN model with a structure of one input layer, three hidden layers, and one output layer [10-36-18-9-1] gives the highest IRI prediction accuracy with root mean square error and coefficient of determination (R2) of 0.117 and 0.92, respectively. Finally, a sensitivity analysis was performed to evaluate the impact of each input variable on the accuracy of IRI prediction for JPCP sections, and it was found that the most influential variables are initial IRI, pavement age, mean and standard deviation of humidity, standard deviation of evaporation, mean and standard deviation of freezing index, pavement compressive strength, ratio between pavement and base layers thickness, and finally an estimated parameter called site factor which is a function of (age, freezing index and soil percentage passing sieve no. 200).

Published
2024
Full Text
View/download PDF

25. Lessons Learned From Shared Decision-Making With Oral Anticoagulants: Viewpoint on Suggestions for the Development of Oral Chemotherapy Decision Aids.

Author

McLoughlin DE, Moreno Echevarria FM, and Badawy SM

Subjects
Humans, Administration, Oral, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Neoplasms drug therapy, Patient Preference, Anticoagulants administration & dosage, Anticoagulants adverse effects, Decision Making, Shared, Decision Support Techniques
Abstract

Oral chemotherapy is commonly prescribed, and by using decision aids (DAs), clinicians can facilitate shared decision-making (SDM) to align treatment choices with patient goals and values. Although products exist commercially, little evidence informs the development of DAs targeting the unique challenges of oral chemotherapy. To address this gap in the literature, our objective was to review DAs developed for oral anticoagulation, DA use in oncology, and patient preference surveys to guide the development of DAs for oral chemotherapy. We focused on reviewing SDM, patient preferences, and specifically the development, efficacy, and patient experience of DAs in oral anticoagulation and oncologic conditions, ultimately including conclusions and data from 30 peer-reviewed publications in our viewpoint paper. We found that effective DAs in oral anticoagulation improved knowledge, lowered decisional conflict, increased adherence, and covered a broad range of SDM elements; however, limited information on patient experience was a common shortcoming. In oncology, DAs increased knowledge and aligned decisions with the values of the patients. Ineffective oncology DAs provided general, unclear, or overly optimistic information, while providing "too much" information was not shown to do harm. Patients preferred DAs that included pros and cons, side effects, questions to ask, and expected quality of life changes. In developing DAs for oral chemotherapy, patients should be included in the development process, and DA content should be specifically tailored to patient preferences. Providing DAs ahead of appointments proved more effective than during, and additional considerations included addressing barriers to efficacy. There is a need for evidence-based DAs to facilitate SDM for patients considering oral chemotherapy. Developers should use data from studies in oral anticoagulation, oncology, and preference surveys to optimize SDM., (©Daniel E McLoughlin, Fabiola M Moreno Echevarria, Sherif M Badawy. Originally published in JMIR Cancer (https://cancer.jmir.org), 11.09.2024.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results